CBD Calmed Inflamed Intestines in Mice Without Affecting Normal Gut Movement | Research

The takeaway

CBD selectively reduced gut hypermotility caused by inflammation without slowing normal intestinal movement, working through CB1 receptors and the FAAH enzyme pathway.

Read this if you have inflammatory bowel symptoms and want to understand the preclinical science behind CBD for gut health.

CBD reduced inflamed gut hypermotility but did not affect normal intestinal movement

What the researchers found

Researchers tested CBD's effects on both normal and inflamed mouse intestines. In healthy mice, CBD had no effect on gut motility, meaning normal digestive movement was unaffected.

However, in mice with croton oil-induced intestinal inflammation, CBD normalized the excessive gut motility (hypermotility) that accompanies inflammation. This selectivity, affecting only abnormal movement while leaving normal function intact, is a desirable property for any potential medication.

The anti-hypermotility effect was blocked by the CB1 receptor antagonist rimonabant but not by the CB2 antagonist, opioid antagonist, or alpha2-adrenergic antagonist, indicating a CB1-mediated mechanism. CBD's effect was also abolished when FAAH (the enzyme that breaks down anandamide) was inhibited, suggesting CBD works by enhancing anandamide levels through FAAH.

In isolated intestinal tissue, CBD inhibited acetylcholine-induced contractions from both normal and inflamed intestines, showing it has direct smooth muscle effects as well.

Why it matters

Inflammatory bowel diseases cause painful gut hypermotility. Most anti-motility drugs (like loperamide) reduce all gut movement, including normal digestion. CBD's selective action on only inflamed, hyperactive intestines suggests it could relieve symptoms without causing constipation.

The numbers in context

CBD normalized croton oil-induced hypermotility. Effect blocked by rimonabant (CB1 antagonist). Effect NOT blocked by CB2 antagonist, naloxone (opioid), or yohimbine (alpha2-adrenergic). Effect abolished by FAAH inhibition.

How the study worked

In vivo gut motility was measured by tracking an orally administered fluorescent marker through the small intestine. Inflammation was induced with croton oil. Various receptor antagonists and enzyme inhibitors were used to identify the mechanism. In vitro contractility was measured in isolated ileum.

What this study cannot tell us

Mouse intestinal inflammation models don't fully replicate human IBD. The doses used may not correspond to achievable human doses. Only acute effects were examined. The croton oil model is a chemical irritant, not an immune-mediated model like Crohn's disease.

How to read the evidence

This is a well-designed animal study with thorough mechanistic investigation, providing moderate preclinical evidence that requires human validation.

When this study was published

Published in 2008. Clinical trials of CBD for IBD have since been initiated, with some showing promising results for symptom management.

The bigger picture

This study provided preclinical support for CBD in inflammatory bowel disease, a condition where patients frequently report using cannabis for symptom relief. The selective mechanism, affecting only inflamed tissue, is particularly relevant for drug development.

Questions still open

Does CBD show the same selective anti-motility effect in human IBD? Would oral CBD at standard doses achieve sufficient intestinal concentrations? Could CBD complement existing IBD medications?

Common questions

Could CBD help with IBS or Crohn's disease?

This mouse study showed CBD selectively reduced inflammation-driven gut overactivity, which is promising for conditions like IBD. However, mouse models don't fully represent human disease, and clinical trial evidence for CBD in IBD is still developing.

Why is it significant that CBD didn't affect normal gut movement?

Most anti-diarrheal drugs (like Imodium) slow all gut movement, causing constipation. CBD's selective action on only inflamed, overactive intestines means it could potentially relieve symptoms without disrupting normal digestion.

Read the original research

Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice.

British journal of pharmacology, 154(5), 1001-8

View on PubMed ↗Publisher’s paper ↗

Citation

Capasso, R; Borrelli, F; Aviello, G; Romano, B; Scalisi, C; Capasso, F; Izzo, A A. (2008). Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice.. British journal of pharmacology, 154(5), 1001-8. https://doi.org/10.1038/bjp.2008.177